TheraRadar
← Back
Data updated: Jun 28, 2026

VELZEN PHARMA PVT

Generics

VELZEN PHARMA PVT is a generic drug manufacturer focused on Cardiovascular.

1991
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

VELZEN PHARMA PVT's Key Drugs

VELZEN PHARMA PVT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

VELZEN PHARMA PVT's Recent FDA Approvals

New NDA/BLA approvals for VELZEN PHARMA PVT over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

VELZEN PHARMA PVT's Therapeutic Areas

VELZEN PHARMA PVT's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 100%
1 drugs

VELZEN PHARMA PVT's Top Competitors

VELZEN PHARMA PVT's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

VELZEN PHARMA PVT Pipeline Snapshot

Active clinical trials for VELZEN PHARMA PVT across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling